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This study compared the efficacy and safety of the fluticasone propionate 125/~g pressurized metered ose inhaler 
(pMDI) propelled by either hydrofluoroalkane (HFA) 134a or chlorofluorocarbon (CFC) propellants, in adult 
patients with asthma. HFA 134a is a non-ozone depleting propellant used as a replacement for the CFC propellants 
11 and 12 which are being phased out in accordance with the Montreal Protocol. 
Three hundred and eighty patients with mild to moderate asthma nd 'room for improvement' in their treatment 
were randomized to receive fluticasone propionate 250 pg twice daily via pMDIs propelled by either CFC 
propellants I1 and 12 01 = 195) or HFA 134a (n = 185). 
Fluticasone propionate significantly improved lung function over the 4-week treatment period in both treatment 
groups. The improvement in mean morning peak expiratory flow (PEF) after 7 days of treatment was 
approximately 12 I min - t  in both groups, rising to approximately 22 1 min -1 at the end of the 4-week treatment 
period. The adjusted mean difference between the two formulations over weeks 1--4 was -1  I rain - I  (90% 
confidence interval: -7 ,  5 1 min-I) ,  confirming their equivalence. Clinical comparability was also demonstrated 
with respect to secondary efficacy variables, including daily symptom scores, evening PEF and clinic visit expiratory 
measurements. There were no clinically relevant differences in adverse vents or serum cortisol evels between the 
two groups. 
The fluticasone propionate 125 Fg HFA 134a pMDI is an effective and well tolerated product and is a suitable 
replacement for the ftuticasone propionate 125/ag CFC pMDI at a microgram equivalent dose. 
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Introduction 
The non-ozone depleting hydrofluoroalkane (HFA) pro- 
pellant, HFA 134a, has been selected as the alternative 
propellant for Glaxo Wellcome's pressurized metered-dose 
inhalers (pMDI). Preclinical and clinical studies have 
shown that HFA 134a behaves as an inert gas with a 
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similar pharmacokinetic and safety profile to that of the 
CFC propellants 11 and 12 (1,2). The pharmaceutical 
performance of pMDI fomulations containing HFA 134a 
as the propellant is also equivalent to that of the 
corresponding CFC pMDI product (3). 
Fluticasone propionate 250 ~g twice daily is an effective 
and well tolerated treatment for mild to moderate asthma. 
Furthermore, at this dose, fluticasone propionate is at least 
as effective as twice the microgram dose of budesonide and 
beclomethasone dipropionate in terms of improvements in 
lung function and symptom control (4,5). The objective of 
this study was to compare the efficacy and tolerability of 
fluticasone propionate 250/~g twice daily administered via a 
125 ~Lg pMDI propelled by either HFA 134a or the CFC 
propellants 11 and 12. 
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Materials and methods  
SUBJECTS 
Adult patients aged >18 years were selected from out- 
patient clinics at 62 centres in France. Written informed 
consent was obtained from each patient before their 
participation i the study. 
All subjects had a documented history of mild to 
moderate asthma requiring at least 400-1000/lg day - I  of 
inhaled beclomethasone dipropionate or equivalent, and a 
forced expiratory volume in I sec (FEV0 of between 50- 
90% of the predicted value. They also had to be able to use 
a pMDI correctly. Patients were excluded if they had 
unstable asthma, had been hospitalized, or had taken oral 
or parenteral corticosteroids or antibiotics in the preceding 
4 weeks. Patients who had received oral or parenteral 
corticosteroids on two or more occasions in the preceding 3 
months, had a known hypersensitivity to any element of the 
formulations used in the study, or had received other 
research medication i the 12 weeks prior to the study were 
also excluded. 
Participants atisfying the above criteria exchanged 
their usual bronchodilator for salbutamol (administered 
vi~. a CFC pMDI), to be taken as required to relieve 
symptoms, for a 2-week run-in period. At the end of this 
period, study entry requirements were to demonstrate a 
mean morning peak expiratory flow (PEF) of <90% of the 
maximum PEF after inhalation of 400 or 800 tLg of 
salbutamol, and for at least four puffs of salbutamol to 
have been taken over the previous 7 days. These criteria 
were used to indicate that there was 'room for improve- 
ment' in patients treatment (6). 
STUDY DESIGN AND PROCEDURES 
This multi-centre, double-blind, parallel-group study was 
approved for all study centres by the relevant Ethics 
Committee. Following the run-in period, patients were 
randomly assigned to 4 weeks of pMDI treatment with 
fluticasone propionate 250 pg twice daily, propelled by 
either HFA 134a or the CFC propellants 11 and 12. The 
study treatment was used as a replacement for the patients' 
current inhaled corticosteriod therapy and the use of 
short-acting fl2-agonists, anti-cholinergics or oral/parent- 
eral corticosteroids was not permitted uring the study 
period. Salbutamol was provided as rescue therapy for the 
duration of the study. All other concurrent medication 
was permitted. Appropriate large volume spacer devices 
(Volumatic TM) were supplied for those patients who 
required them. Those participants who used spacers did 
so throughout he treatment period and their use was 
recorded. 
Patients were given a mini-Wright peak flow meter to use 
at home, and recorded the best of three measurements of 
morning and evening PEF on a daily record card. PEF 
measurements were made before taking the study medica- 
tion and, where possible, at least 4 h after the last dose of 
salbutamol. Asthma symptoms and use of rescue salbuta- 
mol were also recorded on the daily record card. 
The clinic was attended 'by all participants on four 
scheduled occasions: at the start and end of the 2-week run- 
in period, at the end of the 4-week treatment period, and 
after a 2-week follow-up period. At each clinic visit, FEVI 
and PEF were measured and airway reversibility was 
determined at the end of the run-in period. Airway 
reversibility was assessed by recording PEF using a mini- 
Wright peak flow meter, before and after the administra- 
tion of salbutamol 400 llg via a pMDI (or 800 pg via a dry 
powder inhaler). Patients were therefore requested to 
refrain from using their salbutamol for at least 4 h before 
each clinic visit and any long-acting bronchodilator for 12 h 
beforehand. Where possible, all lung function assessments 
were made at the same time of day, preferably in the 
morning. The highest of three values was recorded for each 
lung function parameter. 
At the third clinic visit (at the end of the treatment 
period), treatment efficacy was assessed subjectively by both 
the patient and the physician. The assessment categories 
were 'very effective', effective', 'satisfactory', 'ineffective' or
'very ineffective', scoring 1-5 respectively. 
Fasting venous blood and urine ,samples were collected 
between 08.00 and 10.00 hours at the start of the run-in 
period and at the end of treatment for routine urinary and 
biochemical nalysis. Serum samples were also analysed for 
cortisol concentrations. 
DATA ANALYSES 
Data analyses were performed on the intent-to-treat 
population. Hypothesis testing was used to examine the 
possible equivalence of fluticasone propionate pMDls 
using either HFA 134a or CFCs as propellants. The 
primary efficacy parameter was mean morning PEF. 
Equivalence was established if the 90% confidence interval 
(CI) for the difference between mean morning PEF 
measurements for the two treatments was within + 15 1 
min- t. Basing calculations on a standard eviation of 30- 
40 1 min- i  125 evaluable patients per treatment group were 
required to detect equivalence and to ensure a power of 
80% (6,7). 
Morning PEF and clinic visit PEF and FEVI were 
adjusted for comparison of the two treatment groups using 
analysis of covariance, with baseline, gender, age and centre 
(pooled) as covariates. The baseline covariate for mean 
morning PEF was the mean value of the last week of the 
run-in period, and for clinic visit PEF and FEV1 results, the 
measurements taken at the end of the run-in period were 
used. Following logarithmic transformation, serum cortisol 
data were also analysed using analysis of covariance. 
The Wilcoxon rank sum test was used to assess the 
differences between treatment groups for symptom scores 
over weeks 1-4, percentage of days and nights with no 
additional bronchodilator mediation and patient and 
physician assessment of efficacy. The Wilcoxon rank sum 
test was stratified by centre (pooled) using the van Elteren 
method to provide a significance t st (8). 
TABLE 1. Patient demographic characteristics 
FLUTICASONE PROPIONATE 250 #g HFA 134a pMDI $31 
Fluticasone propionate 
HFA 134a pMDI 
Fluticasone propionate 
CFC pMDI 
Number of patients 185 195 
Males: female (%) 96:89 (52:48) 97:98 (50:50) 
Age (years) 
Mean + SD 45 __+ 15 42 _+ 15 
Range 18-80 18-73 
Use of Volumatic TM spacer (no. of pts) 60 (33%) 52 (27%) 
History of smoking (no. of pts): 
Never 118 (64%) 112 (57%) 
Ex-smoker 57 (31%) 65 (33%) 
Current 10 (5%) 18 (9%) 
Duration of reversible airways obstruction (no. of pts; years): 
0-10 83 (45%) 86 (44%) 
11-20 57 (31%) 56 (29%) 
21-30 26 (14%) 25 (13%) 
>30 19 (10%) 28 (14%) 
Baseline FEV I l [mean _ SD] 2.31 +0"75 2.40+0.71 
Asthma medication continued into the study (no. of pts): 
Long-acting fl2-agonists 29 (16%) 36 (18%) 
Methylxanthines 25 (14%) 32 (16%) 
Sodium cromoglycate I (< 1%) 4 (2%) 
CFC, chlorofluorcarbon; HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler; SO, standard eviation. 
Resu l ts  
Of the 380 patients randomized to receive treatment, 185 
were assigned fluticasone propionate pMDIs propelled by 
the new propellant HFA 134a, and 195 received devices 
containing the CFC propellants I1 and 12. The treatment 
groups were well matched with respect to their demo- 
graphic details (Table I). Eight patients were withdrawn 
from the study, four from each group. The reasons for 
withdrawal were adverse events (two patients from each 
group), failure to return (one patient from each group), and 
unknown (one patient in each group). 
DIARY CARD MEASUREMENTS 
The two formulations of fluticasone propionate were shown 
to be equivalent in terms of the primary efficacy variable, 
mean morning PEF, despite the fact that there were 
baseline differences between the two groups. The estimated 
difference between means for the two treatment groups 
(adjusted for baseline, gender, age and centre) during weeks 
1-4 was -1  1 min - I  (90% CI: -7 ,  5 1 min-I).  
Mean morning PEF improved over the study period in 
both treatment groups. After 4 weeks of treatment, PEF 
values had increased from baseline by 23 and 22 I min-  I in 
the HFA 134a and CFC groups, respectively. Improve- 
ments in morning PEF of 12 and 13 1 min- i  occurred in the 
HFA 134a and CFC groups, respectively, asearly as 1 week 
after starting treatment. Mean morning PEF values are 
shown in Fig. 1 and adjusted means over weeks 1-4 are 
presented in Table 2. 
Secondary efficacy variables including mean evening 
PEF, and percentage predicted mean morning and evening 
PEF also showed comparable adjusted increases in both 
treatment groups (Table 2). The use of large volume spacers 
had no significant effect on any efficacy variable (P = 0.191). 
Both treatment groups showed an increase in the 
percentage of days and nights with no additional bronch- 
odilator medication. At the start of treatment, the HFA 
134a pMDI group had a median of 29% of days with no 
additional bronchodilator use which rose to 83% by the 
end of week 4, whereas values in the CFC pMDI group rose 
from 43 to 83% over the same time period. The percentage 
of nights with no additional bronchodilator use increased 
from a median of 71% at baseline to 100% at the end of 
treatment in both groups. 
The median daytime and night-time symptom score was 
zero (no symptoms) in both treatment groups, at the start 
and end of treatment. 
CLINIC VISIT DATA 
By the end of the 4oweek treatment period, clinic visit FEVI 
had increased by 0-15 and 0" 19 1 from baseline values in the 
HFA 134a and CFC pMDI groups, respectively. The two 
formulations were therefore comparable (90% CI for the 
treatment difference: -0 .11,  0.02 1). 
Clinic visit PEF also increased during the treatment 
period. The adjusted increases from baseline were 27 and 
34 1 min - '  in the HFA 134a and CFC pMDI groups, 
respectively. 
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FIc. 1. Mean morning peak expiratory flow 0aEF) during the 2-week run-in period and 4 weeks of treatment with fluticasone 
propionate 250/~g twice daily administered via a chlorofluorocarbon (CFC) or hydrofluoroalkane (HFA) 134a pressurized 
metered ose inhaler (pMDI). 
TABLE 2. Change in diary card measurements of peak expiratory flow (PEF) in patients with mild to moderate asthma treated 
with fluticasone propionate 250 Izg twice daily for 4 weeks administered via a chlorofluorocarbon (CFC) or hydrofluoroalkane 
(HFA) 134a pressurized metered ose inhaler (pMDI) 
Fluticasone Fluticasone Adjusted mean 
propionate propionate difference* 
HFA 134a CFC pMDI  (-+sE) 
pMDI (n = 185) (n = 194) 
90% CI P value* 
Mean morning PEF 
Baseline mean +_so 371 -+ 107 391 _ 102 
Adjusted mean* +SE 399+3 400+__2 -- 1 +4 --7,5 0~839 
Mean evening PEF 
Baseline mean + so 388 _ 108 406_ 99 
Adjusted mean* -t- SE 410 -t- 2 412 _ 2 -- 3 -I- 3 -- 8,3 0"432 
% predicted mean moring PEF 
Baseline mean __+so 74+ 17 77+ 16 
Adjusted mean* +__SE 79--+ 1 80-+ 1 0-+ 1 -- 1,1 0"775 
% predicted mean evening PEF 
Baseline mean -+so 85-+ 17 ~; 87+ 15 
Adjusted mean* _+SE 89-+ I 90--+ 1 -- 1 _ 1 --2,1 0-425 
*Adjusted for baseline, gender, age and centre. 
tp vaiue calculated using analysis of covariance. 
184 patients. 
CI, confidence interval; so, standard deviation; sE, standard error. 
The two formulations of fiuticasone propionate were also 
shown to be comparable with respect o the patients' and 
physicians' assessment of efficacy. The median score for 
both formulations was 2 'effective', and there was no 
statistically significant difference between the two formula- 
tions. 
SAFETY 
The number of adverse events reported during treatment 
was similar for the two treatment groups [48 patients (26%) 
in the HFA 134a group and 52 patients (27%) in the CFC 
group]. The most commonly occurring adverse event was 
FLUTICASONE PROPIONATE 250 /~g HFA 134a pMDI $33 
TABLE 3. Serum cortisol evels (nmol 1- i) at baseline and after 4 weeks of treatment .-- .  
Fluticasone propionate 
HFA 134a pMDI 
Fluticasone propionate 
CFC pMDI 
Number of patients 172 188 
Mean value at baseline 474 508 
Mean value after treatment 469 495 
Mean change* - 5.03 - 13.19 
*Mean change calculated from value post-treatment minus the baseline value. 
CFC, chlorofluorocarbon; HFA, hydrofluoroalkane; pMDI, pressurized metered-dose inhaler. 
bronchitis [four patients (2%) and six patients (3%) in 
the two groups, respectively]. Adverse events com- 
monly associated with inhaled corticosteriod therapy 
(including candidiasis of the mouth, hoarseness and rash/ 
skin eruption) were reported in <1% of patients in both 
groups. There were no reports of paradoxical bronchos- 
pasm. Eight cases of taste disturbance were noted: five in 
the HFA 134a pMDI group and three in the CFC pMDI 
group. 
No clinically relevant changes in mean serum cortisol 
values were apparent in either group over the treatment 
period (Table 3). In addition, no clinically relevant changes 
in vital signs were reported in either treatment group. 
Discussion 
The results of this study demonstrate that fluticasone 
propionate formulated with the new non-CFC propellant, 
HFA 134a, at a dose of 250/~g twice daily, is as effective as 
the CFC formulation in treating patients with mild to 
moderate asthma who have room for improvement on 
existing therapy. Patients on inhaled corticosteroid therapy 
at a beclomethasone dosage of 400-1000 t~g day - t  or 
equivalent showed comparable improvements in all efficacy 
variables following treatment with either formulation of 
fluticasone propionate. In addition, both propellants were 
well tolerated. These results are in accordance with other 
studies which demonstrate that the fluticasone propionate 
HFA 134a pMDI is a suitable alternative to the CFC 
pMDI (9-11). 
In order to establish true clinical equivalence of 
fluticasone propionate when propelled by HFA 134a or 
the CFC propellants 11 and 12, it was necessary for patients 
to show room for improvement. The reason for this is that 
if both treatments cannot be shown to improve symptoms, 
or if both treatments have maximum possible effect, the 
results may be interpreted in a different way, and 
considered as not being truly indicative of equivalence 
(12). The main purpose of the run-in period was to establish 
that all patients entering the study had room for improve- 
ment. Comparison of the maximum achievable PEF in 
response to salbutamol 400 or 800 pg and the mean PEF 
recorded uring the study indicated that 90% of patients 
had not reached 95% of their maximum achievable PEF. 
This confirmed that comparisons between the two pMDI 
groups were not made on the plateau of the dose response 
curve .  
Thus, the comparable improvements observed in this 
study with the new HFA 134a formulation of fluticasone 
propionate and the existing CFC formulation are indicative 
of effective clinical equivalence. The improvement in the 
primary efficacy variable (mean morning PEF) was 
observed as early as 1 week after starting treatment and 
continued throughout the treatment period. This fast onset 
of action is a distinguishing feature of fluticasone propio- 
nate, and has been similarly reported in another study 
investigating the same dose of fluticasone propionate 
administered via the pressurized inhaler (CFC propellants) 
and via the Diskhaler TM inhaler (4). Secondary efficacy 
variables howing similar improvements from baseline in 
both treatment groups include diary card measurements 
and clinic visit FEVI and PEF measurements. 
Both formulations of fluticasone propionate were well 
tolerated, with a similar overall incidence and pattern of 
adverse vents. Of the adverse events that are frequently 
associated with inhaled corticosteroid therapy, only 
candidiasis, hoarseness and rash/skin eruption were re- 
ported and these were in a very low percentage of patients 
in both groups. There was no evidence of paradoxical 
bronchospasm, an adverse vent which has previously been 
reported with pressurized inhalers (13). No clinically 
relevant effects on serum cortisol or vital signs were 
observed in "either treatmen[ group. However, it is now 
known that measurement of 08-00-10.00 hours serum 
cortisol evels is not the best marker of safety (14). 
The pharmaceutical performance of the fluticasone 
propionate 125/~g HFA 134a pMDI is comparable to that 
of the CFC pMDI, particularly with respect to particle size 
distribution and fine particle mass (3). However, a slightly 
lower systemic exposure has been demonstrated for the 
HFA 134a compared with the CFC fluticasone propionate 
pMDI (15). These data are supported by the results of this 
large multicentre study showing that the fluticasone 
propionate HFA 134a pMDI has less tendency to reduce 
serum cortisol levels than the CFC product without a 
detrimental effect on clinically relevant lung function. These 
data indicate that transition from the fluticasone propio- 
nate CFC to HFA 134a pMDI is possible at a microgram 
equivalent dose. 
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The results of this study demonstrate that fluticasone 
propionate formulated with a new non-CFC propella'nt, 
HFA 134a, is an effective treatment for patients with mild 
to moderate asthma. The data indicate that substitution of 
ozone-depleting CFCs with HFA 134a in pMDls delivering 
fluticasone propionate is possible without affecting treat- 
ment efficacy or tolerability. 
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